Are exosomes FDA-approved? Clinical evidence and regulation
Exosomes are not FDA-approved for therapeutic use. This guide covers their role in disease, the biomarker and therapeutic research, early trials and the regulatory picture.

Key takeaways.
- Exosome therapies are not FDA-approved for therapeutic use.
- Exosomes take part in disease, including cancer spread, as well as in normal physiology.
- They are being studied as liquid biopsy biomarkers and as drug delivery vehicles.
- As of 2024, human therapeutic studies were at the Phase I and Phase II stage.
- Early trial results have been mixed, and long-term human safety data are lacking.
- The FDA handles exosome products case by case and has no exosome-specific guidance documents.
Exosomes take part in disease
Exosomes are active in disease as well as in health. In cancer research, tumor-derived exosomes are described as helping prepare distant organs for metastasis. A 2015 study reported that adhesion molecules called integrins on tumor exosomes influence which organs they reach.
This matters for safety thinking. The source lists the oncogenic potential of exosomes from transformed or engineered cell lines as a point that needs evaluation.
Diagnostic research
Exosomes are being studied as liquid biopsy markers. A liquid biopsy looks for disease information in a fluid such as blood or urine instead of a tissue sample.
The interest comes from two features. Exosomal cargo is protected by a membrane, and surface markers can indicate the cell of origin.
Therapeutic research and early trials
Exosomes are being studied as drug delivery vehicles and as therapeutic agents in their own right. Much of the therapeutic work uses exosomes derived from mesenchymal stem cells.
As of 2024, the source describes Phase I and Phase II trials underway or recently completed. In severe COVID-19, results were mixed. Some trials reported trends toward benefit and others showed none. Serious adverse events were reported as rare, but long-term human safety data are lacking.
The regulatory position
Exosome therapies are not FDA-approved for therapeutic use. The source describes the FDA as handling exosome products case by case, generally as biological products, without guidance documents specific to exosomes.
Open issues include batch-to-batch consistency, validated potency assays, stability in storage and safety evaluation. Potency assays are tests that measure a product's biological activity. ISEV position papers offer scientific consensus, but they are not regulatory guidance.
Educational content for healthcare professionals. Not a treatment recommendation. Exosome therapies are not FDA-approved for therapeutic use.
This guide covers the what and the why.
The how is taught live. The webinar and live training go deeper on:
- What the regulatory position means for a clinical practice
- How to discuss evidence and FDA status with patients
- Consent and documentation principles
- Evaluating product claims and quality data
- Safety screening considerations
Common questions.
Are exosome therapies FDA-approved?
What clinical trials exist for exosomes?
What is an exosome liquid biopsy?
Sources
- Hoshino, A., et al. (2015). Tumour exosome integrins determine organotropic metastasis. Nature, 527(7578), 329-335.
- Melo, S. A., et al. (2015). Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature, 523(7559), 177-182.
- Alvarez-Erviti, L., et al. (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotechnology, 29(4), 341-345.
Keep reading.
Exosome · 3 min read
What is still unknown about exosomes?
Exosome science has clear gaps: mixed vesicle populations, uncertain fate in the body, poorly defined dose-response and weak standardization. Each one matters for clinical claims.
Start the lessonExosome · 3 min read
What is exosome therapy?
A plain introduction to exosome therapy: what exosomes are, why researchers study them as a cell-free alternative to stem cells, and where regulation stands.
Start the lessonExosome · 3 min read
How are exosomes thought to work?
The proposed mechanisms of exosomes in plain terms: cargo delivery, immune modulation, new vessel growth and cell signaling. Most of this evidence is preclinical.
Start the lessonReady for the hands-on detail?
Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.